Skip to content
Medical Health Aged Care

Monash Expert: SPHERE welcomes increased Medicare support for Long-Acting Reversible Contraceptive (LARC)

Monash University 2 mins read

Monash University’s SPHERE Centre of Research Excellence Director Professor Danielle Mazza AM has welcomed the Australian Government’s announcement of increased Medicare support for Long-Acting Reversible Contraceptive (LARC).

 

From 1 November 2025, the Medicare rebate for four existing Medicare items covering insertion and removal of LARCs is being increased significantly. 

 

Medicare item numbers are also being added to cover insertion and removal of LARCs by nurse practitioners.

 

Additionally if the insertion or removal and associated consultation is bulk billed there will be a 40 per cent loading added to the rebate. This bulk billing incentive is being provided to try and remove current, sometimes large, out of pocket costs incurred by women who choose to use LARC for contraception.  

Professor Danielle Mazza AM, Head of General Practice at Monash University, Chief Investigator and Director of the SPHERE Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care and Australian National and Victorian Women’s Health Advisory Council member
Contact: +61 3 9903 4840 or [email protected]
Read more of Professor Mazza’s commentary at Monash Lens
 

  • General practice

  • Women's Health

  • Endometriosis Care

  • The need to improve access to both medical and surgical abortion and long acting reversible contraception

The following can be attributed to Professor Mazza AM:

“I welcome this week’s landmark implementation of Medicare changes designed to support increased provision of and access to Long Acting Reversible Contraceptives intrauterine devices and implants (LARCs) in Australia.

 

“While LARC is widely recognised as the most effective form of contraception – 99 per cent effective – the uptake in Australia has been very low, at just 11 per cent of women aged 14-49 years, and worse in rural areas.

 

“In many European countries, LARC use amongst women of reproductive age is more than 30 per cent, and in Denmark it is 39 per cent. 

 

“One of the main reasons LARC use is so low in Australia is likely the small number of trained providers in community settings. The Government changes will create a new environment to benefit Australian women.

 

“I’d like to congratulate the Government for implementing what are really meaningful initiatives. 

 

“These changes have come about in response to calls by SPHERE, GP providers and the Royal Australian College of General Practitioners for the Government to support primary care provision of LARC. 

 

“They also complement a range of other initiatives designed to increase LARC provision in general practice and community settings including: training scholarships, the establishment of LARC Centres of Excellence in each state that will offer a rapid referral option for LARC insertion and more capacity to train primary care practitioners, and ongoing support for SPHERE’s online community of practice supporting primary care providers in relation to LARC and medication abortion provision (AusCAPPs).”

 

These reforms are part of the Strengthening Medicare Women’s Health Package announced in the February 2025 Federal Budget. SPHERE has collated a handy guide here. 

 

For more Monash media stories visit our news & events site: monash.edu/news 

For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or [email protected]

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.